Sustained efficacy and seroconversion with the Toll-like receptor 7 agonist GS-9620 in the Woodchuck model of chronic hepatitis B

Stephan Menne1,*,†, Daniel B. Tumas2,‡, Katherine H. Liu3, Linta Thampi4, Dalal AlDeghaither1, Betty H. Baldwin3, Christine A. Bellezza3, Paul J. Cote1, Jim Zheng4, Randall Halcomb5, Abigail Fosdick5, Simon P. Fletcher2, Stephane Daffis2, Li Li7, Peng Yue7, Grushenka H.I. Wolfgang5, Bud C. Tennant3

1Department of Microbiology and Immunology, Georgetown University Medical Center, Washington, DC 20057, United States; 2Department of Biology, Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404, United States; 3Department of Clinical Sciences, Gastrointestinal Unit, College of Veterinary Medicine, Cornell University, Ithaca, NY 14853, United States; 4Department of Drug Safety Evaluation, Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404, United States; 5Department of Drug Metabolism, Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404, United States; 6Department of Drug Safety Evaluation, Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404, United States; 7Department of Biomarkers, Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404, United States

Background & Aims: New therapies for chronic hepatitis B (CHB) are urgently needed since current treatments rarely lead to cure. We evaluated whether the oral small molecule toll-like receptor (TLR7) agonist GS-9620 could induce durable antiviral efficacy in woodchucks chronically infected with woodchuck hepatitis virus (WHV), a hepadnavirus closely related to human hepatitis B virus (HBV).

Methods: After evaluating the pharmacokinetics, pharmacodynamics and tolerability of oral GS-9620 in uninfected woodchucks, adult woodchucks chronically infected with WHV (n = 7 per group) were dosed with GS-9620 or placebo for 4 or 8 weeks with different treatment schedules.

Results: GS-9620 treatment induced rapid, marked and sustained reduction in serum viral DNA (mean maximal 6.2 log10 reduction), and hepatic WHV DNA replicative intermediates, WHV cccDNA and WHV RNA, as well as loss of detectable serum WHV surface antigen (WHsAg). GS-9620 treatment also induced a sustained antibody response against WHsAg in a subset of animals. Strikingly, treatment reduced the incidence of hepatocellular carcinoma (HCC) from 71% in the placebo group to 8% in GS-9620-treated woodchucks with sustained viral load reduction. GS-9620 treatment was associated with reversible increases in serum liver enzymes and thrombocytopenia, and induced intrahepatic CD8⁺ T cell, NK cell, B cell and interferon response transcriptional signatures.

Conclusions: The data demonstrate that short duration, finite treatment with the oral TLR7 agonist GS-9620 can induce a sustained antiviral response in the woodchuck model of CHB, and support investigation of this compound as a therapeutic approach to attain a functional cure in CHB patients. © 2015 European Association for the Study of the Liver. Published by Elsevier B.V. Open access under CC BY-NC-ND license.

Keywords: TLR7; Hepatitis B virus; Hepatocellular carcinoma; Immuno-modulation; Seroconversion; Woodchuck animal model.

Introduction

An estimated 350 million people have chronic hepatitis B virus infection (CHB), and over 500,000 people die each year due to HBV-associated liver diseases, such as cirrhosis and hepatocellular carcinoma (HCC) [1]. Current therapeutics for CHB are limited to nucleos(t)ides and interferon-alpha (IFN-α); these reduce viral load, improve long-term outcome, but rarely lead to a cure [2]. Immunologic control of CHB, recognized as a “functional cure,” is defined by control of viremia, loss of HBV surface antigenemia (HBsAg), and seroconversion to anti-HBs antibody (HBsAb) and occurs in only 2–3% of patients per year with anti-virals [2]. Functional cure with long-term IFN treatment occurs in <10% of patients at doses associated with treatment-limiting adverse effects [2]. There is therefore an urgent need for a curative therapy.

Natural infection with woodchuck hepatitis virus (WHV), a hepadnavirus closely related to the HBV, occurs in the Eastern
Research Article

woodchuck (Marmota monax). Chronic WHV infection is a model for studying CHB, hepadnavirus-associated HCC, and is used to evaluate HBV therapeutics [3]. Importantly, comparison of the intrahepatic transcriptional profiles in woodchucks and humans with chronic hepadnaviral infection identified important parallels in the antiviral immune responses and demonstrated molecular similarities in HCC induced by WHV and HBV [4]. As this establishes the translational value of the WHV model, we utilized it to explore therapeutic immunomodulation with the small molecule TLR7 agonist GS-9620.

TLR7 is expressed predominantly in plasmacytoid dendritic cells (pDCs) and B lymphocytes and recognizes viral single-stranded RNA [5]. TLR7 activation induces innate and adaptive immune responses via induction of specific cytokines (including multiple IFN-α subtypes [6]) and chemokines, activation of B cells [7], and cross-priming of cytotoxic lymphocytes [8]. GS-9620 is a selective, oral small molecule TLR7 agonist that has activity in rodents, nonhuman primates and humans [9–12]. A single dosing regimen (three times a week for 8 weeks) of GS-9620 has previously been evaluated in a small number of chimpanzees (n = 3) with CHB [10]. Here we report a placebo-controlled study in which the activity of different regimens and treatment durations of GS-9620 were evaluated in woodchucks chronically infected with WHV. Importantly, this model provided a unique opportunity to evaluate the antiviral activity of GS-9620 in a model of vertical transmission and to determine treatment impact on development of hepadnavirus-associated HCC.

Materials and methods

Investigational drug

GS-9620, (8-(3-(pyrrolidin-1-ylmethyl)benzyl)-4-amino-2-butoxy-7,8-dihydropyridin-6(5H)-one), a small molecule, selective TLR7 agonist, was manufactured by Gilead Sciences, Inc. [9]. Doses were administered in a liquid diet (1 mg/ml; 79002 Liquid Woodchuck Control Diet, Dyets, Inc., Bethlehem, PA) in a dose volume of 10 ml. Placebo-treated woodchucks were administered liquid diet alone.

Woodchuck TLR7 cloning and sequencing

Total RNA was isolated from woodchuck PBMC using RNeasy extraction kit (QIAGEN, Redwood City, CA) and DNA was synthesized using SuperScript III First-Strand Synthesis System (Life Technologies, Chicago, IL) according to the manufacturer’s instructions. Woodchuck TLR7 (wTLR7) sequence was identified by a PCR-based strategy using various primers that were designed based on highly conserved sequences between human TLR7 (NM_016562.3) and mouse TLR7 (NM_133211.3). The 5’- and 3’-ends of wTLR7 were identified using 5’ and 3’ RACE System kits respectively according to the manufacturer’s instructions (Life Technologies, Chicago, IL). All amplified PCR fragments were sequenced to obtain the complete wTLR7 sequence, deposited into NCBI (Accession TRD Prior to Publication). wTLR7 was synthesized and cloned into pUNO1-hTLR7-HA3x vector (InvivoGen, San Diego, CA) in place of human TLR7 to generate pUNO1-wTLR7-HA3x.

HEK293 TLR7 assay

Human embryonic kidney (HEK) 293 cells (CRL1573-ATCC) were seeded in 96 well plates in DMEM-GlutaMAX-I supplemented with 10% FBS. Eight hours post-seeding, the cells were co-transfected with either human TLR7 (pUNO1-hTLR7-HA3x) or wTLR7 (pUNO1-wTLR7-HA3x) along with the NF-κB luciferase reporter pNFκB2-Luc (InvivoGen, San Diego, CA) using TransIT™-293 transfection reagent (Minus, Pittsburgh, PA) according to the manufacturer’s instructions. Eighteen hours post-transfection the cells were stimulated with various concentrations of GS-9620 for 6 h. Cells were lysed using ONE-Glo Luciferase assay system (Promega, Madison, WI) and NF-κB luciferase activity measured using a VICTOR X Light Luminescence plate reader (Perkin-Elmer, Waltham, MA).

Animals

Protocols were approved by the Institutional Animal Care and Use Committee of Cornell University. Neonatal woodchucks were infected at 3 days of age with a WHV7P1 inoculum containing 5 × 10⁶ WID50 of WHV strain WHV7-11 and were then raised to adulthood prior to use in this study. All infected woodchucks were monitored serologically through 1 year post infection. At the start of the study all woodchucks had antibody to WHV core antigen (anti-WHc antibody), were negative for antibody to WHV surface antigen (anti-WHS antibody; WHSAb), had serum WHV DNA levels >10⁶ ge/ml and detectable WHV surface antigen (WHSAg) at pretreatment, and were free of HCC by ultrasound liver examination and serum gamma glutamyl transferase (GGT). Uninfected control woodchucks were negative for anti-WHc antibody, anti-WHS antibodies, WHSAg, and WHV DNA.

Single dose pharmacokinetic (PK) and pharmacodynamic (PD) study in uninfected woodchucks

Uninfected healthy, adult male woodchucks (n = 3 per dose group) were orally administered 1, 5, or 10 mg/kg of GS-9620. Evaluations included clinical observations, clinical pathology, pharmacokinetics and pharmacodynamics. Serum levels of GS-9620 were measured over time to calculate maximum serum concentration (Cmax) and exposure, calculated as area under the serum concentration vs. time curve (AUClast).

Efficacy study in woodchucks chronically infected with WHV

The study design is described in Table 1. Briefly, five groups of woodchucks (n = 7 per group, mixed sex) were treated with GS-9620 for approximately 4 weeks (groups 1, 2, and 3) or 8 weeks (groups 4 and 5) and evaluations continued through 35 weeks (time of scheduled euthanasia). Woodchucks that developed HCC were euthanized; HCC was diagnosed by ultrasound and serum GGT and confirmed at necropsy. Woodchucks that died unexpectedly during the study were evaluated by necropsy. Serum GS-9620 levels were evaluated at week 4, 4 h post-dose, the approximate time of peak exposure.

Determination of GS-9620 in serum

Woodchuck serum was mixed with acetonitrile containing an internal standard. After protein precipitation and centrifugation, the supernatant was mixed with water with 0.1% formic acid. An aliquot was injected to a TSQ Ultra Quantum LC/MS/MS system (Thermo Finnigan, San Jose, CA).

Clinical pathology

Clinical pathology was assessed at pretreatment, approximately weekly during treatment (24 h post-dose), at least 1 and 2 weeks after the last dose, and approximately monthly through the end of the 35 week study [13].

WHV serum viremia levels

WHV DNA was quantified by two different methods depending on concentration: dot blot hybridization or real-time PCR assay on a 7500 Real-Time PCR System instrument (Applied Biosystems, Foster City, CA) as described previously [14].

Hepatic levels of WHV nucleic acids

Liver levels of WHV DNA replicative intermediates (RI), WHV cccDNA, and WHV RNA were determined in liver biopsies collected 2 weeks prior to treatment and at selected time-points during and after treatment. Biopsies were obtained under general anesthesia with a 16-gauge needle directed by ultrasound imaging. Biopsy specimens for WHV nucleic acid analyses were placed immediately in liquid nitrogen and stored at −70 °C. WHV RNA was measured quantitatively by Northern blot hybridization as previously described [15,16]. WHV DNA RI
and WHV cccDNA was quantitatively determined by Southern blot hybridization as previously described [17]. WHV cccDNA levels were expressed as a percentage change from pretreatment level.

**WHV serology**

WHsAg and anti-WHs antibody were assessed approximately weekly through week 10 and then monthly through week 35 using WHV-specific enzyme immunoassays [18]. Serum WHsAg was quantified by ELISA against a standard curve for purified WHsAg (lower sensitivity: ca. 30 ng/ml serum). Anti-WHsAb titer was quantified by ELISA as described [18].

**Statistical analyses for repeat-dose study**

Analysis of variance (ANOVA) models using SAS PROC GLM were performed to compare treatment effects of continuous PD response variables, serum and liver viral load variables. ANOVA was also performed to relate binary endpoints, such as HCC incidence with PD response and with serum and liver viral load variables. ANOVA was also performed to relate binary endpoints, such as HCC incidence with PD response and with serum and liver viral load variables. ANOVA was also performed to relate binary endpoints, such as HCC incidence with PD response and with serum and liver viral load variables. ANOVA was also performed to relate binary endpoints, such as HCC incidence with PD response and with serum and liver viral load variables. ANOVA was also performed to relate binary endpoints, such as HCC incidence with PD response and with serum and liver viral load variables.

**Pharmacodynamic (PD) analyses**

Methods for quantitative RT-PCR and RNA-Seq analysis are provided in the Supplementary Materials.

**RNA-Seq data archiving**

The RNA-Seq data has been deposited in the NCBI GEO under accession number GSE67935.

**Results**

**Single dose pharmacokinetics, pharmacodynamics and tolerability of GS-9620 in uninfected adult woodchucks**

After single oral doses of 1, 5 and 10 mg/kg, the average Cmax of GS-9620 was 4.8 ± 1.4 nM, 23.6 ± 27.0 nM, and 660 ± 907 nM, respectively, with an average Tmax at 3.7, 5.5, and 3.3 h, respectively. GS-9620 exposure was roughly dose-proportional at 1 mg/kg but greater than proportional at 10 mg/kg (Supplementary Fig. 1A). The pharmacodynamic (PD) response was determined by measuring induction of mRNA levels of the IFN-stimulated genes (ISGs) 2′-5′-OAS and MxA in whole blood (Supplementary Fig. 2B and C, respectively). Reagents to measure woodchuck serum IFN-α protein were not available; however, 2′-5′-OAS and MxA RNA levels are sensitive and established markers of IFN-α induction in other species. In uninfected woodchucks, the average maximum fold increase from pretreatment was 6.7, 11.8, and 11.0 for 2′-5′-OAS after GS-9620 doses of 1, 5 and 10 mg/kg, respectively, and 30.1, 35.6, and 45.2, respectively, for MxA, with peak induction at 24 h (Supplementary Fig. 2B and C). GS-9620 showed a similar dose response induction of 2′-5′-OAS and MxA in PBMCs across other species, including cynomolgus monkeys, chimpanzees and humans (Supplementary Table 1) [10–12]. GS-9620 has comparable in vitro potency for woodchuck and human TLR7 (Supplementary Fig. 1).

GS-9620 induced transient increases in body temperature in at least some woodchucks at each dose level (1, 5, and 10 mg/kg). In addition, at the 5 and 10 mg/kg, GS-9620 induced transient hematological changes, including reversible decreases in platelets (26% and 75% decrease at 5 and 10 mg/kg, respectively) and lymphocytes (72% decrease at 10 mg/kg). Transient lymphocyte changes were consistent with trafficking and/or margination associated with TLR7 induced chemokines [19,20]. Based on these single dose assessments, 5 mg/kg was chosen for the efficacy study.

**GS-9620 efficacy study in woodchucks chronically infected with WHV**

The efficacy study evaluated adult woodchucks (12–14 months of age) chronically infected with WHV. In order to model vertical transmission in humans, chronic infection in these adult animals was established by neonatal WHV infection (see Materials and methods). As described in Table 1, five groups of woodchucks (n = 7 per group, both males and females) were treated with either GS-9620 (groups 2–5) or placebo (group 1). Groups 3–5 comprised chronically infected animals treated with GS-9620 at different schedules. Control groups included WHV-infected animals treated with placebo (group 1), and uninfected animals treated with GS-9620 (group 2). Due to thrombocytopenia noted during the first 2 weeks of GS-9620 treatment in some animals (data not shown), dosing was interrupted for 9 to 10 days for groups 2 and 3, and then reinitiated with dose reduction to 2.5 mg/kg in groups 2, 3, and 4. Group 5, treated weekly, was not dose reduced. No further changes in dose or schedule occurred. Treatment duration was thus approximately 4 weeks (groups 1, 2, and 3) or 8 weeks (groups 4 and 5) and evaluations continued through 35 weeks (time of scheduled euthanasia).

The serum exposure of GS-9620 at 5 and 2.5 mg/kg (Supplementary Table 2) was consistent with single dose data in uninfected woodchucks (Supplementary Fig. 2A). GS-9620 administration induced statistically significant (p < 0.05) increases in 2′-5′-OAS and MxA RNA transcripts in all treated animals (Fig. 1; Supplementary Fig. 3) with the exception of four WHV-infected animals in group 4 (QOD × 8 weeks). Because of these four non-responding animals, group 4 generally had lower but still significant (p < 0.05) induction of 2′-5′-OAS, but did not have significant induction of MxA. Induction of 2′-5′-OAS and MxA was statistically significantly higher in GS-9620-treated uninfected animals (group 2) vs. WHV-infected woodchucks (groups 3, 4, and 5) (all p < 0.05).
Tolerability of GS-9620 treatment in woodchucks chronically infected with WHV

The most common adverse events were transient, dose-dependent thrombocytopenia and increases in serum liver enzymes (AST, ALT, GGT, and SDH). Reductions in platelets occurred primarily at 5 mg/kg and, when present, recovered between weekly treatments. Increases in serum liver enzymes occurred in all study groups including placebo-treated WHV-infected woodchucks, but were more consistent in WHV-infected, GS-9620-treated woodchucks (Fig. 2; Supplementary Fig. 8). The increases in liver enzymes observed in placebo-treated, WHV-infected woodchucks were likely related to WHV infection, as described previously [21]. In GS-9620-treated, WHV-infected woodchucks, transient serum liver enzyme increases generally occurred during the treatment period and coincided with viral load reduction (Fig. 2; Supplementary Fig. 8). Liver enzyme increases were likely due to a combination of spontaneous increases associated with WHV infection as noted in placebo-treated woodchucks (group 1), possible GS-9620 effects as observed in GS-9620-treated, uninfected woodchucks (group 2), or hepatocellular effects related to an antiviral immune response.

No deaths occurred in GS-9620-treated uninfected woodchucks (group 2) or in GS-9620-treated, WHV-infected woodchucks treated for approximately 4 weeks (group 3). Two woodchucks in the placebo-treated WHV-infected group and one GS-9620-treated WHV-infected animal in group 5 were euthanized due to HCC. A non-treatment related death occurred in group 5 from hemorrhage caused by a liver biopsy procedure. Mortality or euthanasia occurred in two other WHV-infected woodchucks treated with GS-9620 for 8 weeks, one at the end of treatment (group 5) and one during the post-treatment evaluation period (group 4). The former animal had microscopic findings consistent with a bacterial/viral infection that likely contributed to the death. The other animal, based on its clinical chemistries and liver pathology (chronic inflammation, necrosis...
and nodular regeneration) had diminished liver function which contributed to its poor clinical condition leading to euthanasia. Because of the complex disease pathogenesis of chronic WHV infection in woodchucks and inflammatory processes associated with chronic infection, the role of GS-9620 treatment in these two mortalities is undetermined.

**Antiviral efficacy of GS-9620 treatment in woodchucks chronically infected with WHV**

GS-9620 treatment induced marked, sustained reductions in serum WHV DNA noted as early as the first week of treatment. GS-9620 induced reductions in viremia occurred in nearly all GS-9620-treated woodchucks by week 4 (Fig. 3 and Table 2). In contrast, the placebo group had no changes in serum WHV DNA. WHV-infected woodchucks treated QOD for 4 weeks (group 3) had a uniformly marked antiviral response with a mean maximal viral load reduction of 6.2 log10. At the end of the study (week 35), this group had a mean 4.8 log10 reduction in viral load. Mean viral load in this group during weeks 3–35 were significantly reduced compared to pretreatment (all \( p < 0.05 \)) and the placebo control group at weeks 2–35 (all \( p < 0.05 \)). Similar efficacy occurred in animals that completed weekly (QW) GS-9620 treatment for 8 weeks (group 5) (Fig. 3 and Table 2). In this group (group 5), GS-9620 treatment caused statistically significant reductions in viral load compared to pretreatment and the placebo control group at weeks 2–35 (all \( p < 0.05 \)) with a mean maximal viral load reduction of 6.1 log10 and a sustained mean 5.0 log10 viral load reduction at the end of the study (week 35). Strikingly, after completion of only 4 or 8 weeks of GS-9620 treatment, suppression of viral load was sustained through the end of the study (week 35) in all woodchucks in group 3 (QOD × 4 weeks), and in 4 of 5 woodchucks in group 5 (QW × 8 weeks) that completed treatment (Fig. 3C and E).

In woodchucks treated QOD every other week (QOD QOW) (group 4), three of seven animals had marked decreases in viral load (Fig. 3D). Two of these three animals survived to week 35; one maintained a 2 log10 decrease in viral load, whereas viremia returned to pretreatment levels by week 18 in the other animal (Fig. 3D). These three woodchucks had a PD response comparable to GS-9620-treated WHV-infected woodchucks in groups 3 and 5, whereas the four woodchucks in this group that did not have a reduction in viral load had a lower PD response based on MxA and 2’5’-OAS RNA induction (SupplementaryFig. 3D, I, and K). It is not clear why these four animals had lower PD responses to GS-9620, although drug exposure (Supplementary Table 2), animal gender and relative tumor burden (Supplementary Fig. 8) do not appear to be contributing factors.

**Fig. 3. Serum viral DNA levels in WHV-infected woodchucks.** (A) Group geometric means and (B–E) individual animal levels. Geometric means were calculated from animals that completed treatment and had an antiviral response to GS-9620 in the treatment groups (≥ 1 log10 reduction in serum viral load at more than one time point evaluated; Table 2). Group 2 animals were not infected with WHV and were therefore not included in the plots. Tx: treatment.
GS-9620 treatment reduced the hepatic levels of WHV nucleic acids

Compared with placebo-treated woodchucks, levels of hepatic WHV DNA RI, WHV cccDNA, and WHV RNA were significantly (all \( p < 0.005 \)) decreased in groups 3 and 5 at week 35, but not in group 4 (Fig. 4A; Supplementary Figs. 4–6). MxA and 2’-5’-OAS RNA induction negatively correlated with the maximal reduction in serum WHV DNA, liver WHV RI, and WHV cccDNA (all \( p < 0.0001; r^2 > 0.55 \)) and positively correlated with liver WHV RNA (\( p < 0.0001; r^2 > 0.48 \)).

GS-9620 treatment reduced serum WHsAg levels

GS-9620 treatment caused pronounced and sustained reductions in WHsAg (Fig. 5A and B, Supplementary Fig. 7). Through week 35, GS-9620 treatment of group 3 woodchucks (QOD \( \times 4 \) weeks) induced complete loss of detectable (<30 ng/ml) WHsAg in all animals (7 of 7 woodchucks). Loss of detectable WHsAg also occurred in two of the three group 4 woodchucks (QOD \( \times 8 \) weeks) with a viral response to treatment, and four of the five group 5 woodchucks (QW \( \times 8 \) weeks) that completed treatment. Loss of detectable WHsAg occurred as early as 2 weeks after the initiation of treatment. Mean WHsAg was significantly reduced in groups 3 and 5 at weeks 3–35 and weeks 2–35, respectively, when compared with the pretreatment level (all \( p < 0.05 \)), and at weeks 1–35 and 2–35, respectively, when compared with the placebo control (all \( p < 0.05 \)).

GS-9620 treatment induced anti-WHs antibody seroconversion in a subset of animals

Seroconversion to WHsAb was observed in a subset of GS-9620-treated woodchucks, but not in placebo-treated woodchucks (Fig. 5C). Anti-WHsAb was detected in 3 of 7 woodchucks in group 3, and 3 of 5 woodchucks in group 5. In these animals, anti-WHsAb was first noted as early as week 2, and as late as week 21. Anti-WHsAb was also detected in 1 of the 3 woodchucks in group 4 that had viral load reduction in responses to treatment. Anti-WHsAb titers in most woodchucks increased gradually through week 35.

Fig. 4. Intrahepatic levels of (A) WHV DNA replicative intermediates (RI), (B) WHV cccDNA, and (C) WHV RNA in WHV-infected woodchucks. Geometric means were calculated from animals that completed treatment and had an antiviral response to GS-9620 in the treatment groups (>1 log_{10} reduction in serum viral load at more than one time point evaluated; Table 2). Group 2 animals were not infected with WHV and were therefore not included in the plots. The \( p \) values denote the level of statistical significance at week 35 relative to the placebo group.

Table 2. Summary of efficacy parameters and hepatocellular carcinoma (HCC) incidence in GS-9620-treated woodchucks.

<table>
<thead>
<tr>
<th>Group</th>
<th>Mean maximal viral load log reduction in animals with antiviral response</th>
<th>Number of animals</th>
<th>HCC incidence</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Sustained viral response</td>
<td>Loss of serum WHsAg</td>
<td>Anti-WHs antibody</td>
</tr>
<tr>
<td>1</td>
<td>n.a.</td>
<td>0/7</td>
<td>0/7</td>
</tr>
<tr>
<td>2</td>
<td>n.a.</td>
<td>n.a.</td>
<td>n.a.</td>
</tr>
<tr>
<td>3</td>
<td>6.2 ± 1.1 (n = 7)</td>
<td>7/7</td>
<td>7/7</td>
</tr>
<tr>
<td>4</td>
<td>6.0 ± 0.8 (n = 3)</td>
<td>1/3</td>
<td>2/3</td>
</tr>
<tr>
<td>5</td>
<td>6.1 ± 1.8 (n = 5)</td>
<td>4/5</td>
<td>4/5</td>
</tr>
</tbody>
</table>

*Animals with a viral response were defined as any animal that had a \( > 1 \) log_{10} reduction in serum viral load at more than one time point evaluated; data shown are from the animals with a viral response that completed treatment (mortality occurred in two animals in group 5 during the treatment phase). The serum viral load was determined by PCR and the limit of detection for the assay was \( 1 \times 10^5 \) virus genome copies (vge)/ml [14].

Sustained viral response were defined as a \( > 2 \) log_{10} reduction in serum viral load at the end of study (week 35).

Three group 4 animals (\( n = 7 \) total) were defined as having a viral response to treatment.

Group 5 values were derived from the 5 of 7 animals that completed the 8 weeks of treatment.
GS-9620 treatment reduces the incidence of hepatocellular carcinoma in woodchucks chronically infected with WHV

The incidence of HCC was markedly reduced in GS-9620-treated woodchucks (Table 2). In placebo-treated WHV-infected woodchucks, HCC occurred in 5 of the 7 (71%) woodchucks, consistent with the previous observation that nearly all chronic WHV carriers develop HCC over time [22]. In contrast, for all GS-9620-treated woodchucks that completed treatment and had a viral load reduction in response to treatment, the incidence was 2 of 15 (13%). Importantly, in GS-9620-treated woodchucks that had a sustained reduction in viral load, the incidence of HCC was only 1 of 12 (8%) (Table 2).

Intrahepatic transcriptional response to GS-9620 treatment

As outlined in Supplementary Fig. 9, intrahepatic transcriptional profiles of placebo-treated (group 1) and GS-9620-treated (group 5; 5 mg/kg QW) animals were determined by RNA-Seq at various times during the study, and were characterized by a gene module approach [23] and ingenuity pathway analysis (IPA). Modular analysis (Fig. 6) revealed that GS-9620 treatment induced cytotoxic cell (CD8+ T cell/NK cell) (Module, M2.1), T cell (M2.8), myeloid cell lineage (M1.5 and M2.6), B cell (M1.3), and IFN response (M3.1) intrahepatic transcriptional signatures. In contrast, there was modest induction of only neutrophil (M2.2) and IFN response (M3.1) gene signatures in the liver of placebo-treated (group 1) and GS-9620-treated (group 5; 5 mg/kg QW) animals relative to pretreatment (day 0). Columns represent different study days. Spot intensity (red: over-expressed; blue: under-expressed) denotes the percentage of transcripts significantly changed in each module (M) and is defined by the scale bar. Only modules for which >15% of module genes were differentially expressed (absolute fold-change >1.5 with a Benjamini-Hochberg corrected FDR <0.05, and passed a low expression threshold) are displayed. The functional interpretation of each module (taken from reference [23]) is displayed on the right.

Fig. 6. Characterization of intrahepatic transcriptional signature associated with GS-9620 treatment. Modular analysis of transcriptional signatures in the liver of placebo-treated (group 1) and GS-9620-treated (group 5; 5 mg/kg QW) animals relative to pretreatment (day 0). Columns represent different study days. Spot intensity (red: over-expressed; blue: under-expressed) denotes the percentage of transcripts significantly changed in each module (M) and is defined by the scale bar. Only modules for which >15% of module genes were differentially expressed (absolute fold-change >1.5 with a Benjamini-Hochberg corrected FDR <0.05, and passed a low expression threshold) are displayed. The functional interpretation of each module (taken from reference [23]) is displayed on the right.
The activity of CD8+ T cells and/or NK cells. In addition, the intrahepatic induction of IFN-γ-stimulated genes (CXCL9, ubiquitin D; UBD) (Supplementary Fig. 11) as well as various IFN-α/β-stimulated genes (M3.1, Fig. 6) [4], suggests that non-cytolytic mechanisms may also play an important role in the antiviral response to GS-9620 treatment.

**Discussion**

Treatment of WHV-infected woodchucks with GS-9620 resulted in rapid, marked and sustained antiviral response. GS-9620 pharmacodynamic responses were consistent with activation of TLR7 and correlated statistically with antiviral efficacy. Importantly, the magnitude of ISG induction in chronically infected woodchucks was similar to that induced in humans at well tolerated doses (Supplementary Table 1) [11]. Strikingly, in most chronically infected animals GS-9620 induced a multi-log reduction in viral load, WHsAg loss and anti-WHs antibody seroconversion, and reduced cccDNA levels and HCC incidence. Specifically, reductions in viral load occurred in 15 of 19 woodchucks that completed treatment (regardless of regimen) and viral load reductions were sustained through the end of the study in 12 of these 15 woodchucks. Sustained WHsAg loss occurred in 13 of 15 woodchucks that completed treatment. Importantly, in 8 of 13 treated woodchucks with WHsAg loss, induction of WHsAb occurred and persisted. In GS-9620-treated woodchucks that had a sustained reduction in viral load, the incidence of HCC was less than 10% compared to a rate of over 70% in the placebo group.

The antiviral responses induced by GS-9620 are clearly differentiated from those observed with nucleos(t)ides evaluated in the woodchuck model of CHB. While the duration of viral load reduction was markedly longer with GS-9620 compared to similar treatment with nucleos(t)ides, the most important finding was that, in contrast to GS-9620, nucleos(t)ide treatment induced a sustained loss of WHsAg in only a small minority of WHV-infected woodchucks and induction of anti-WHsAb was rare [3,14]. Other therapeutic strategies in this model have included therapeutic vaccination, IL-12 gene therapy and inhibition of PD-L1 [24–26]. Although, in some instances, these therapies have yielded transient reductions in viral load, WHsAg and induction of anti-WHsAb, no single agent has been reported to induce a comparable antiviral response to GS-9620. Most notably, while treatment of chronically infected woodchucks with recombinant woodchuck IFN-α strongly reduced serum WHV DNA and WHsAg in some treated animals, this was a transient response that was not accompanied by anti-WHsAb seroconversion in most woodchucks (Menne S, unpublished data).

Similar to a previous report in HBV-infected chimpanzees [10], GS-9620 treatment in woodchucks was associated with thrombocytopenia and liver enzyme increases. These adverse effects were transient, reversed with dose holiday, had reduced incidence and severity with lower doses, and were monitored by routine clinical laboratory parameters. Increases in liver enzymes were noted in some animals throughout all groups, including placebo-treated animals, and were reversible in most cases without dose reduction or treatment cessation. The mechanism by which GS-9620 treatment caused platelet reductions in woodchucks is not clear. However, recent reports show that TLR7 is expressed in platelets, that TLR7 activation can induce a reduction in platelet count with no influence on thrombotic properties, and these effects enhanced host immune response and survival to viral infection [27]. As elevations in liver enzymes noted in GS-9620-treated animals were temporally associated with reductions in hepatic cccDNA, liver enzyme increases may represent immune-mediated killing of infected hepatocytes. This is consistent with the induction of an intrahepatic cytotoxic CD8+ T cell and/or NK cell transcriprional signature during GS-9620 treatment. Notably, transient increases in liver enzymes often precede clearance of acute hepadnavirus infection in woodchucks, chimpanzees and humans, and are thought to represent development of effective intrahepatic antiviral immunity [28–30].

The results demonstrate that short duration treatment with GS-9620 can induce a durable therapeutic antiviral immune response during chronic hepadnavirus infection. In a previous study in chimpanzees chronically infected with HBV, GS-9620 treatment caused a sustained, albeit less marked reduction in viral load and HBsAg [10]. While studies are ongoing to define the cellular and molecular characteristics of the antiviral response to GS-9620, it likely involves local induction of IFN-α, as well as induction of antiviral NK and CD8+ T cell responses [8,31,32]. In addition, direct activation of B cells by GS-9620 may also be an important mechanism that contributes to viral clearance [33].

In summary, short duration treatment with GS-9620 induced a sustained antiviral response and anti-WHs antibody seroconversion in the woodchuck model of CHB. These data suggest that GS-9620 may have the potential to therapeutically induce sustained immunological control of chronic HBV infection in patients.

**Conflict of interest**

This study was sponsored by Gilead Sciences, Inc. D. Tumas, R. Halcomb, G. Wolfgang, A. Fosdick, J. Zheng, L. Li, P. Yue, S. Daffis, and S. Fletcher are employees of Gilead Sciences, Inc.

**Financial support**

This work was supported by contract N01-AI-05399 to the College of Veterinary Medicine, Cornell University and contract HHSN272201000011L, task order HHSN27200001 (D01) to Georgetown University Medical Center from the National Institute of Allergy and Infectious Diseases (NIAID).

**Author’s contributions**

Participated in research design: S. Menne, D. Tumas, R. Halcomb, G. Wolfgang, B. Tennant. Conducted experiments: B. Baldwin, C. Bellezza (woodchuck procedures), P. Cote (serum WHsAg and anti-WHsAb quantitative data), S. Menne, K. Liu, L. Thampi, D. AlDeghaither (pharmacodynamics sample analysis, serum WHV DNA quantitative data, hepatic WHV nucleic acid quantitative data), J. Zheng (pharmacokinetic sample analysis), S. Daffis (HEK293 TLR evaluation), L. Li, P. Yue, S. Fletcher (RNA-Seq bioinformatics analysis). Performed data analysis: A. Fosdick, S. Menne, D. Tumas, J. Zheng, G. Wolfgang, S. Fletcher. Wrote or contributed to the writing of the manuscript: A. Fosdick, D. Tumas, S. Menne, S. Fletcher.
Acknowledgements

The authors acknowledge Mary A. Ascenzi, Lou Ann Graham, and Erin Graham from Cornell University, as well as Yun Wang and Junming Yang from Georgetown University. Becky Norquist provided medical writing services to Gilead Sciences.

Supplementary data

Supplementary data associated with this article can be found, in the online version, at http://dx.doi.org/10.1016/j.jhep.2014.12.026.

References